Can you take Docefrez with Talquetamab?

The DOCEtaxel in Docefrez has a moderate potential interaction with Alcoholism.

The alcohol content in a dose of docetaxel injection may affect the central nervous system. Cases of intoxication have been reported with some formulations of docetaxel due to the alcohol content. Close monitoring is recommended in alcoholic patients. Consideration should be given to the alcohol content in docetaxel injection on the ability to drive or use machines immediately after the infusion.

The DOCEtaxel in Docefrez has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

The use of docetaxel is contraindicated in patients with a neutrophil count < 1500/mm3. Docetaxel induces dose-related myelosuppression resulting in neutropenia, thrombocytopenia, and anemia. Neutropenia occurs in all patients administered 60-100 mg/m2 of docetaxel. Grade 4 neutropenia (< 500/mm3) occurs in nearly all patients administered 100 mg/m2 of docetaxel. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, or local infection. Therapy should be administered cautiously to patients with compromised bone marrow reserve and should be withheld until neutrophil levels is > 1500/mm3 and/or platelet counts is > 100,000/mm3. A 25% reduction in dosage is recommended during subsequent cycles following severe neutropenia (< 500/mm3). It is recommended to performed frequent blood cell counts on all patients receiving docetaxel.

The DOCEtaxel in Docefrez has a major potential interaction with Fever.

The use of docetaxel is contraindicated in patients with a neutrophil count < 1500/mm3. Docetaxel induces dose-related myelosuppression resulting in neutropenia, thrombocytopenia, and anemia. Neutropenia occurs in all patients administered 60-100 mg/m2 of docetaxel. Grade 4 neutropenia (< 500/mm3) occurs in nearly all patients administered 100 mg/m2 of docetaxel. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, or local infection. Therapy should be administered cautiously to patients with compromised bone marrow reserve and should be withheld until neutrophil levels is > 1500/mm3 and/or platelet counts is > 100,000/mm3. A 25% reduction in dosage is recommended during subsequent cycles following severe neutropenia (< 500/mm3). It is recommended to performed frequent blood cell counts on all patients receiving docetaxel.

The DOCEtaxel in Docefrez has a major potential interaction with Fluid Retention.

Severe fluid retention characterized by peripheral edema, generalized edema, pleural effusion, dyspnea at rest, cardiac tamponade, or abdominal distention due to ascites has been reported during docetaxel therapy. Therapy with docetaxel should be administered cautiously to patients adversely affected by fluid retention. Prophylaxis with a five day dexamethasone premedication regimen is recommended, however, fluid retention has occurred despite this pretreatment.

The DOCEtaxel in Docefrez has a major potential interaction with Infection.

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

Talquetamab has a moderate potential interaction with Infection.

Teclistamab and talquetamab can cause severe, life-threatening, or fatal infections. Patients should be monitored for signs and symptoms of infection prior to and during treatment. Any infection should be treated appropriately. Administer prophylactic antimicrobials according to clinical guidelines.

The DOCEtaxel in Docefrez has a major potential interaction with Liver Disease.

Docetaxel is extensively metabolized by the liver. Total body clearance of docetaxel has been reported to be reduced as much as 27% in patients with mild to moderate hepatic impairment resulting in a 38% increase of docetaxel serum concentration. Patients with elevated transaminase levels (>1.5 times the upper limits of normal) and alkaline phosphatase (>2.5 times the upper limits of normal) should not be administered docetaxel. The incidence of docetaxel related deaths is increased in patients with impaired hepatic function. Bilirubin, transaminase, and alkaline phosphatase levels should be obtained prior to each cycle of docetaxel therapy. Patients with combined abnormalities of transaminases and alkaline phosphatase should not be treated with this agent.

Talquetamab has a moderate potential interaction with Liver Disease.

The effects of severe renal impairment (eGFR less than 30 mL/min) on the pharmacokinetics of teclistamab and talquetamab are unknown. Moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN with any AST) on the pharmacokinetics of teclistamab are unknown. Severe hepatic impairment (total bilirubin greater than 3 times ULN with any AST) on the pharmacokinetics of talquetamab are unknown. Additionally, teclistamab and talquetamab have caused hepatotoxicity, including fatalities. Caution is advised in patients with renal and hepatic impairment. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated.

The DOCEtaxel in Docefrez has a major potential interaction with Macular Edema.

Cystoid macular edema has been reported with the use of docetaxel. Patients with impaired vision should undergo a prompt and comprehensive ophthalmologic examination prior to therapy with this agent. If cystoid macular edema is diagnosed, treatment should be discontinued and appropriate treatment initiated. Alternative non-taxane cancer treatment should be considered.

The DOCEtaxel in Docefrez has a moderate potential interaction with Peripheral Neuropathy.

Severe neurosensory symptoms such as paresthesia, dysesthesia, and pain have been reported during docetaxel therapy. Therapy with docetaxel should be administered cautiously to patients with or predisposition to neurosensory symptoms. Although reversible with discontinuation of docetaxel therapy, the dosage must be adjusted if neurosensory symptoms occur and therapy discontinued if symptoms persist.

Talquetamab has a moderate potential interaction with Renal Dysfunction.

The effects of severe renal impairment (eGFR less than 30 mL/min) on the pharmacokinetics of teclistamab and talquetamab are unknown. Moderate to severe hepatic impairment (total bilirubin greater than 1.5 times ULN with any AST) on the pharmacokinetics of teclistamab are unknown. Severe hepatic impairment (total bilirubin greater than 3 times ULN with any AST) on the pharmacokinetics of talquetamab are unknown. Additionally, teclistamab and talquetamab have caused hepatotoxicity, including fatalities. Caution is advised in patients with renal and hepatic impairment. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated.